PDF Cover

Daprodustat Market

Daprodustat Market

The market for Daprodustat was estimated at $581 million in 2024; it is anticipated to increase to $912 million by 2030, with projections indicating growth to around $1.33 billion by 2035.

Report ID:DS1802569
Author:Debadatta Patel - Senior Consultant
Published Date:July 2025
Datatree
Life Science
Pharmaceutical
Daprodustat
Share
Report Summary
Table of Contents
Methodology
Market Data

Global Daprodustat Market Outlook

Revenue, 2024

$581M

Forecast, 2034

$1.23B

CAGR, 2024 - 2034

7.8%
The Daprodustat industry revenue is expected to be around $626.7 million in 2025 and expected to showcase growth with 7.8% CAGR between 2025 and 2034. The growing trend in the market for daprodustat is being driven by important factors such as the rising cases of renal anemia worldwide and the demand for new treatment options to address it effectively. Major pharmaceutical companies are actively investing in research and development efforts to explore the benefits of daprodustat as a viable alternative therapy option in this field. The introduction of oral medications that target hypoxia inducible factor prolyl hydroxylase has opened up exciting possibilities in the realm of therapeutic solutions and positioned daprodustat as a key player in strategic business initiatives, across the global pharmaceutical sector.

Daprodustat represents an oral medication utilized in treating anemia caused by chronic kidney disease. By inhibiting hypoxia inducible factor prolyl hydroxylase and stimulating erythropoiesis - the body's mechanism for generating new red blood cells - it shows promise, in aiding patients recovery.

Daprodustat market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034

Market Key Insights

  • The Daprodustat market is projected to grow from $581.4 million in 2024 to $1.23 billion in 2034. This represents a CAGR of 7.8%, reflecting rising demand across Chronic Kidney Disease Anemia Management, Ethernet Peripheral Component Interconnect Treatment and Administration in Non-Dialysis Patients.

  • GlaxoSmithKline Plc, FibroGen Inc, and AstraZeneca Plc are among the leading players in this market, shaping its competitive landscape.

  • U.S. and China are the top markets within the Daprodustat market and are expected to observe the growth CAGR of 5.1% to 7.5% between 2024 and 2030.
  • Emerging markets including India, Brazil and South Korea are expected to observe highest growth with CAGR ranging between 9.0% to 10.8%.

  • Transition like The Shift Towards Non-Invasive Treatments is expected to add $80 million to the Daprodustat market growth by 2030

  • The Daprodustat market is set to add $651 million between 2024 and 2034, with manufacturer targeting Anemia in Dialysis & Anemia in Non-dialysis Therapeutic Applications projected to gain a larger market share.
  • With

    rising prevalence of chronic kidney disease, and

    advances in hypoxia-inducible factor prolyl hydroxylase inhibitor, Daprodustat market to expand 112% between 2024 and 2034.

daprodustat market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032

Opportunities in the Daprodustat

The healthcare sector is also being reshaped by technology advancements that extend to how medicationsre administered too. For instance with the introduction of Daprodustat as a next gen hypoxia inducible factor prolyl hydroxylase inhibitor aimed at managing anemia patients stand to gain from these progressions in the field of medicine delivery methods; thereby guaranteeing improved treatment adherence, through tailored dosages and patient involvement enhancements.

Growth Opportunities in North America and Asia Pacific

North America Outlook

North America appears to be a market for the drug known as Daprodustat due to its well developed healthcare infrastructure that presents significant opportunities for increased usage of the medication in the region. One of the advantages of this market is the growing prevalence of renal anemia and chronic kidney diseases that have heightened the demand for advanced treatment solutions like Daprodustat. There is competition in this region from major industry players such as GSK and Pfizer which contributes to a highly competitive environment, in the market segment. The pharmaceutical innovations are driving the market as companies invest heavily in research and development efforts. This trend is creating a market environment, for Daprodustat.

Asia Pacific Outlook

In the Asia Pacific region is set to see growth in the Daprodustat market with great potential opportunities arising from the growing number of patients with anemia and untapped markets in countries like India, China and Japan. The competitive landscape is intense with both local and international pharmaceutical companies, like Sun Pharma and AstraZeneca vying for market share. The main factors fueling this market include healthcare expenditures accelerated urbanization trends and enhanced awareness campaigns concerning anemia and its associated conditions driving the need for advanced treatments such, as Daprodustat.

Market Dynamics and Supply Chain

01

Driver: Rising Prevalence of Chronic Kidney Disease

The demand for Daprodustat has also surged due to an increase in cases of kidney diseases, where Daprodustat is also a key player in managing anemia caused by these conditions effectively as a preferred treatment option. The ability of the drug to control erythropoiesis has also positioned it as a treatment choice for patients, with CKD driving growth in this market sector significantly.


The progress in technology concerning HIF Proly Hydroxylase inhibitors like Doprodustat has also highlighted its capacity to address health ailments beyond cardiovascular disease and cancer as well. Its widened scope of applications has also notably boosted the interest, in Doprodustat within the pharmaceutical sector.

02

Restraint: Regulatory Uncertainties

Regulatory agencies across the globe enforce criteria for safety and effectiveness when it comes to new medications like Daprodustat that is still under investigation for its efficacy and safety profile in different clinical trial stages Any unexpected discoveries during these trials may trigger demands for further research which could cause considerable delays in the approval process Discrepancies in outcomes from various regulatory bodies could also influence the timing of market entry As a result these uncertainties within regulations might hinder the demand, for Daprodustat until its approvals start picking up pace.

03

Opportunity: Tapping into Untapped Markets

The rising demand for anemia treatments is becoming more evident in developing regions where companies producing Daprodustat see opportunities in untapped markets to expand their reach and help address healthcare accessibility issues and low awareness about modern treatment options amid prevalent malnutrition concerns in these areas. There is a shift in focus as organizations like the World Health Organization and other agencies prioritize global efforts to battle anemia worldwide. This makes treatments, like Daprodustat more relevant as they align with the current trends in addressing this health challenge effectively. The markets hold potential for growth opportunities, for Daprodustat producers.

04

Challenge: High Developmental Costs and Risk of Failure

The creation of medications involves significant expenses and risks of failure throughout the process of developing drugs like Daprodustat that demand substantial financial backing for thorough research work and clinical trials along with refining production methods. Nevertheless the potential downside of failure looms large during all phases of development which may dissuade stakeholders leading to challenges in getting market acceptance, for Daprodustat.

Supply Chain Landscape

1
API Production

GlaxoSmithKline

Beijing Mediking

2
Formulation Development

Dr.Reddy's Laboratories

Intas Pharmaceuticals

3
Packaging & Distribution

CordenPharma

Sharp Packaging Services

4
End Use

Renal anemia treatment

Chronic kidney disease management

*The illustration highlights the key stakeholders within the supply chain ecosystem.

Applications of Daprodustat in Chronic Kidney Disease Anemia Management, Ethernet Peripheral Component Interconnect Treatment & Administration in Non-Dialysis Patients

Chronic Kidney Disease Anemia Management

The primary use of daprodustat is in managing and controlling anemia caused by kidney disease. This compound has properties that boost the production of erythropoietin to enhance hemoglobin levels in the body. Leading pharmaceutical companies have capitalized on these benefits to solidify their market presence and set the stage for future advancements, in the healthcare sector.

Ethernet Peripheral Component Interconnect Treatment

Daprodustat is being used in a way to enhance the Ethernet Peripheral Component Interconnect treatment process effectively and efficiently with its advanced features contributing greatly to improved outcomes in PCI treatment worldwide. Leading pharmaceutical companies worldwide have adopted the use of Daprodustat in their treatment approaches. Have established a strong foothold, in the market as a result.

Administration in Non-Dialysis Patients

Many doctors commonly prescribe daprodustat to help patients who do not only require dialysis treatment. This medication has gained trust among healthcare providers due to its proven effectiveness in these situations. The unique healing characteristics of the drug contribute to patient well being and ease of use. This has played a role, in making companies producing daprodustat stand out in the market competition.

Recent Developments

December 2024

GlaxoSmtihkline has shared news of completing the third phase trials for Daprodustat to address anemia resulting from kidney disease. This achievement marks an advancement in the development of new approaches, to managing anemia.

November 2024

AstraZeneca made an advancement by extending its partnership with FibroGen to globally distribute and market Daprodustat for treating anemia in both dialysis dependent and non dialysis dependent CKD patients. This move showcases a shift and collaboration, within the industry to introduce diverse and innovative treatment choices.

October 2024

The FDA has given Apotex approval to produce a form of Daprodustat. This signifies a step forward in making crucial therapies more accessible, to everyone.

The latest developments in anemia care have brought a notable shift in the realm of daprodustat treatment innovation for patients suffering from chronic kidney disease. Recent research advancements, improved clinical trial outcomes, and enhanced regulatory engagement are accelerating its adoption as a safer, more convenient alternative to traditional injectable therapies. These innovations are strengthening its position in the market, offering improved patient compliance and expanded therapeutic potential in CKD-related anemia management.


Impact of Industry Transitions on the Daprodustat Market

As a core segment of the Pharmaceutical industry, the Daprodustat market develops in line with broader industry shifts. Over recent years, transitions such as The Shift Towards Non-Invasive Treatments and A Move Towards Personalized Medicine have redefined priorities across the Pharmaceutical sector, influencing how the Daprodustat market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

The Shift Towards Non-Invasive Treatments

The changing approach to treating kidney disease has brought attention to non invasive treatments like Daprodustat recently. There has been a shift towards better understanding anemia linked to kidney problems and the creation of treatments like Daprodustat that can stimulate erythropoietin naturally without requiring injections. This shift in thinking has greatly influenced care by making treatment options more accessible and convenient, for patients. This industry transition is expected to add $80 million in the industry revenue between 2024 and 2030.
02

A Move Towards Personalized Medicine

In light of the genomic revolution and the progress in precision medicine a significant shift in the healthcare sector involves embracing tailored treatment methods extensively. This shift has noticeably influenced the utilization of Daprodustat. Scientists are investigating reactions to Daprodustat enabling a well informed and personalized strategy, for addressing Anemia linked to chronic kidney disease.

Report Price: $4,200

Related Reports

Loading related reports...